Adarbi Tablet
Azilsartan Medoxomil
40mg
NIPRO JMI Pharma Limited
| Pack size | 20's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 14.00 AED |
Available as:
Indications
Adarbi Tablet is used for:
Hypertension, alone or in combination w/ other antihypertensive agents.
Adult Dose
Adult: Initially 40 mg once daily. May be increased to a max of 80 mg once daily as necessary.
Child Dose
Renal Dose
Renal Impairment
No dose adjustment is required with mild-to-severe renal impairment or end-stage renal disease.
Patients with moderate-to-severe renal impairment are more likely to report high serum creatinine values.
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity. Pregnancy.
Precautions
Abnormally high serum creatinine values more likely reported in patients aged 75 or older
Caution with hyperkalemia
NSAIDs may attenuate antihypertensive response
Coadministration with NSAIDs increase risk of renal impairment including acute renal failure
Hypotension in volume- or salt-depleted patients
In patients with an activated renin-angiotensin system, such as volume-and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment
Impaired renal function
As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals receiving therapy
In patients whose renal function may depend on activity of renin-angiotensin system (eg, patients with severe congestive heart failure, renal artery stenosis, or volume depletion)
Monitoring Parameters
Monitor for worsening renal function in patients with renal impairment.
Monitoring Monitor closely in mild to moderate hepatic impairment (limited information available).
Pregnancy-Lactation
Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)
Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death
Lactation: unknown whether distributed in breast milk, decide on alternate antihypertensive therapy or do not breastfeed
Interactions
In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, may result in deterioration of renal function, including possible acute renal failure; these effects are usually reversible
Monitor renal function periodically in patients receiving azilsartan and NSAID therapy; the antihypertensive effect of angiotensin II receptor antagonists may be attenuated by NSAIDs, including selective COX-2 inhibitors
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy
Most patients receiving combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy; in general, avoid combined use of RAS inhibitors; closely monitor blood pressure, renal function and electrolytes in patients receiving therapy and other agents that affect the RAS
Do not coadminister aliskiren with azilsartan in patients with diabetes; avoid use of aliskiren with azilsartan in patients with renal impairment (GFR <60 mL/min)
Contraindicated (2)
aliskiren
sparsentan
Serious - Use Alternative (14)
aliskiren
benazepril
captopril
enalapril
fosinopril
lisinopril
lithium
lofexidine
moexipril
perindopril
potassium phosphates, IV
quinapril
ramipril
trandolapril
Adverse Effects
Side effects of Azilsartan Medoxomil :
1-10%
Diarrhea (2%)
<1%
Nausea,Asthenia,Fatigue,Muscle spasm,Dizziness,Postural hypotension,Cough
Mechanism of Action
Angiotensin II blocker; displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water absorption, and hypertrophic responses.
May induce more complete inhibition of renin-angiotensin system compared with ACE inhibitors; does not affect response to bradykinin.
Inhibits the pressor effects of an angiotensin II infusion in a dose-related manner.
Note
Adarbi 40mg Tablet manufactured by NIPRO JMI Pharma Limited. Its generic name is Azilsartan Medoxomil. Adarbi is availble in Bangladesh.
Farmaco BD drug index information on Adarbi Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.